Global Hormone Replacement Therapy Market Overview

The Global Hormone Replacement Therapy Market size is expected to grow from USD 31.71 billion in 2023 to USD 55.42 billion by 2032, at a CAGR of 6.4% during the forecast period (2024-2032).

Hormone replacement therapy, or HRT, addresses hormonal imbalances by introducing hormones your body no longer naturally produces. Primarily used to manage menopausal symptoms in women assigned female at birth (AFAB), HRT combats hot flashes, night sweats, vaginal dryness, and mood swings. It can also be part of a treatment plan for transgender and non-binary individuals seeking to develop typically female secondary sex characteristics.

A key driver is the burgeoning geriatric population, particularly women approaching menopause. HRT is a well-established therapy for mitigating symptoms like hot flashes, night sweats, and vaginal dryness, all of which significantly impact quality of life.

Beyond menopause, rising awareness of hormonal imbalances across all age groups is propelling the HRT market forward. This awareness is coupled with increasing disposable income in many regions, making HRT a more attainable option for a wider range of patients. Furthermore, the growing prevalence of hormonal disorders like hypothyroidism and hypogonadism is creating new use cases for HRT beyond just menopause.

Market Dynamics And Key Factors for the Hormone Replacement Therapy Market

Drivers:

If women begin HRT around menopause, the risk is very low, and it appears to provide cardiovascular and bone-protective benefits. Although it is not recommended that women over the age of 60 begin HRT, the WHI trial found that those who do so do not seem to be at an elevated risk of cardiovascular events or mortality. Moreover, HRT also alleviates menopause-related illnesses such as hot flushes, fatigue, osteoporosis, and also reduces the chances of heart diseases thus, driving the growth of the hormone replacement therapy market in the forecast period.

Furthermore, one of the developments in the global market adopted by the leading market players is the introduction of gel-based formulation for estrogen patches and other products. The introduction of an estradiol gel formulation, which is mostly given for low doses and patients who are resistant to oral estrogen therapy, also contributes to the market's growth. Estradiol gels have acquired FDA approval for the treatment of menopausal symptoms with a percutaneous estradiol gel that is easy to administer and has minimal skin sensitivities. For instance, the medicine Estrasorb contains a liposomal formulation that is administered to the thigh's skin.

Restraints:

The lack of whichever hormone is being blocked or inactivated causes negative effects. These side effects are comparable to those associated with menopause, which is the body's natural decrease in estrogen production as it gets older. Hot flashes, nocturnal sweats, weight gain, vaginal dryness, and headache are all possible side effects. Hormone therapy is responsible for some adverse effects. Nausea, hair loss or thinning, muscular pains and joint discomfort, and, more gravely, blood clots and an increased risk of uterine/endometrial cancer are some of the symptoms that might occur thus, hampering the growth of the hormone replacement therapy market over the projected period.

Opportunities:

Increased unmet hormone replacement demands in developing countries, as well as growing awareness of the treatment of hormone abnormalities, drive pharmaceutical companies to introduce new advanced drugs to the global market. Furthermore, the growth in menopause and hormone deficiency problems in key countries has encouraged manufacturers to introduce new goods, such as combination therapy products, to replace the everyday usage of long-acting parenteral medications. For instance, Myovant Sciences announced that in May 2021, FDA has approved its medicine MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. This innovative drug was developed with association with Pfizer. Partnerships and the introduction of new hormone treatment therapies are expected to create opportunities for market players.

Segmentation Analysis of Hormone Replacement Therapy Market

By Route of Administration, the oral segment is anticipated to lead the growth of the hormone replacement therapy market during the projected period. Tablets are the most common as well as the simplest form of taking HRT. For men administration of testosterone is done orally, and for women, oral medication is the most common form of estrogen replacement therapy. Moreover, manufacturers have acknowledged the ease of oral administration of drugs, resulting in large-scale production of oral drugs thus, supporting the growth of the segment.

By HRT Type, the estrogen segment is expected to have the highest share of the HRT market over the analysis timeframe. Menopause symptoms are becoming more common among women all over the world. Many doctors will prescribe an estrogen-containing medicine for menopause. Hormone therapy can help alleviate the symptoms of menopause by replacing the declining estrogen. Estrogen may aid in the prevention of bone loss after menopause thus, strengthening the development of the segment.

By Medical Condition, the menopause segment is anticipated to dominate through the projected timeframe. Menopause isn't a disease. From a female's reproductive years to the next stage of life, it's a normal evolution. Many women pass through menopause without the need for treatment. However, if the transition generates uncomfortable or distracting symptoms, there are several therapy options. HRT is the most common method utilized to treat symptoms that arises due to menopause such as bone thinning, or osteoporosis, sleep problems, mood changes, and others. According to a study published in BioMed Central, by the year 2030, 1.2 billion women will be menopausal or postmenopausal. Furthermore, it is believed that roughly 40-50 million women in the United States have experienced vasomotor symptoms thus, supporting the growth of the segment.

Regional Analysis of Hormone Replacement Therapy Market

North America reigns supreme in the global hormone replacement therapy (HRT) market, boasting a staggering share of around 41% of the total revenue. This dominance can be attributed to a confluence of factors.

North America has a large and growing geriatric population, especially women nearing menopause. HRT is a well-established treatment for alleviating the often-debilitating symptoms of menopause, including hot flashes, night sweats, and vaginal dryness. With a significant portion of the population seeking solutions to these issues, the demand for HRT naturally surges.

North America has a relatively strong level of knowledge about hormonal health among different age groups. This increased understanding, along with increasing disposable incomes, allows a broader group of patients to view HRT as a possible treatment choice. This pertains not just to symptoms of menopause but also includes hormonal imbalances such as hypothyroidism and hypogonadism, which are being diagnosed more frequently. The North American market is fueled by ongoing innovation in hormone replacement therapy drug delivery systems. Pharmaceutical companies are creating easier-to-use alternatives such as patches, gels, and implants. This broadens the available treatments beyond conventional medications, accommodating personal choices and potentially enhancing the adherence to HRT schedules.

Players Covered In Hormone Replacement Therapy Market

• AbbVie Inc.
• Pfizer Inc.
• Merck & Co., Inc.
• Novo Nordisk A/S
• Amgen Inc.
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Mylan N.V.
• Sanofi S.A.
• AstraZeneca PLC
• Eli Lilly and Company
• GlaxoSmithKline plc (GSK)
• Roche Holding AG
• Endo International plc
• Organon & Co.
• TherapeuticsMD, Inc.
• Perrigo Company plc
• Ferring Pharmaceuticals
• Actavis (part of Allergan plc)
• Endoceutics (part of Duchesnay)
• Bionovo, Inc.
• Seren Pharmaceuticals
• Mithra Pharmaceuticals
• Besins Healthcare

Key Industry Developments in Hormone Replacement Therapy Market

• In January 2024, Ascendis Pharma A/S announced that YORVIPATH (palopegteriparatide, developed as TransCon PTH), a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism, in the Germany and Austria.
• In June 2023, Pfizer Inc. announced that DUAVEE (conjugated estrogens/bazedoxifene), an estrogen-based menopause hormone therapy, is back in stock in the United States, with improved packaging.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Therapy Type
 3.2 By Indication
 3.3 By Route Of Administration
 3.4 By Distribution Channel

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  3.5.1 Drivers
  3.5.2 Restraints
  3.5.3 Opportunities
  3.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 4: Hormone Replacement Therapy Market by Therapy Type
 4.1 Hormone Replacement Therapy Market Overview Snapshot and Growth Engine
 4.2 Hormone Replacement Therapy Market Overview
 4.3 Estrogen and Combinations Replacement Therapy
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Estrogen and Combinations Replacement Therapy: Grographic Segmentation
 4.4 Growth Hormone Replacement Therapy
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Growth Hormone Replacement Therapy: Grographic Segmentation
 4.5 Thyroid Hormone Replacement Therapy
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Thyroid Hormone Replacement Therapy: Grographic Segmentation
 4.6 Testosterone Hormone Replacement Therapy
  4.6.1 Introduction and Market Overview
  4.6.2 Historic and Forecasted Market Size (2017-2032F)
  4.6.3 Key Market Trends, Growth Factors and Opportunities
  4.6.4 Testosterone Hormone Replacement Therapy: Grographic Segmentation

Chapter 5: Hormone Replacement Therapy Market by Indication
 5.1 Hormone Replacement Therapy Market Overview Snapshot and Growth Engine
 5.2 Hormone Replacement Therapy Market Overview
 5.3 Menopause
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Menopause: Grographic Segmentation
 5.4 Hypothyroidism
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Hypothyroidism: Grographic Segmentation
 5.5 Male Hypogonadism
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Male Hypogonadism: Grographic Segmentation
 5.6 Growth Hormone Deficiency
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size(2017-2032F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Growth Hormone Deficiency: Grographic Segmentation

Chapter 6: Hormone Replacement Therapy Market by Route Of Administration
 6.1 Hormone Replacement Therapy Market Overview Snapshot and Growth Engine
 6.2 Hormone Replacement Therapy Market Overview
 6.3 Oral
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Oral: Grographic Segmentation
 6.4 Transdermal
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Transdermal: Grographic Segmentation
 6.5 Parenteral
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Parenteral: Grographic Segmentation

Chapter 7: Hormone Replacement Therapy Market by Distribution Channel
 7.1 Hormone Replacement Therapy Market Overview Snapshot and Growth Engine
 7.2 Hormone Replacement Therapy Market Overview
 7.3 Hospital Pharmacies
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size (2017-2032F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Hospital Pharmacies: Grographic Segmentation
 7.4 Retails Pharmacies & Stores
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size (2017-2032F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Retails Pharmacies & Stores: Grographic Segmentation
 7.5 Online Pharmacies
  7.5.1 Introduction and Market Overview
  7.5.2 Historic and Forecasted Market Size (2017-2032F)
  7.5.3 Key Market Trends, Growth Factors and Opportunities
  7.5.4 Online Pharmacies: Grographic Segmentation

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Positioning
  8.1.2 Hormone Replacement Therapy Sales and Market Share By Players
  8.1.3 Industry BCG Matrix
  8.1.4 Ansoff Matrix
  8.1.5 Hormone Replacement Therapy Industry Concentration Ratio (CR5 and HHI)
  8.1.6 Top 5 Hormone Replacement Therapy Players Market Share
  8.1.7 Mergers and Acquisitions
  8.1.8 Business Strategies By Top Players
 8.2 ABBOTT LABORATORIES
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Operating Business Segments
  8.2.5 Product Portfolio
  8.2.6 Business Performance
  8.2.7 Key Strategic Moves and Recent Developments
  8.2.8 SWOT Analysis
 8.3 BAYER AG
 8.4 ELI LILLY AND COMPANY
 8.5 F. HOFFMANN-LA ROCHE LTD. (GENENTECH
 8.6 INC.)
 8.7 HISAMITSU PHARMACEUTICAL CO. INC. (NOVEN PHARMACEUTICALS INC.)
 8.8 MERCK KGAA
 8.9 MYLAN N.V. (VIATRIS INC.)
 8.10 NOVARTIS INTERNATIONAL AG
 8.11 NOVO NORDISK A/S
 8.12 PFIZER INC.

Chapter 9: Global Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2017-2032
 9.1 Market Overview
 9.2 Historic and Forecasted Market Size By Therapy Type
  9.2.1 Estrogen and Combinations Replacement Therapy
  9.2.2 Growth Hormone Replacement Therapy
  9.2.3 Thyroid Hormone Replacement Therapy
  9.2.4 Testosterone Hormone Replacement Therapy
 9.3 Historic and Forecasted Market Size By Indication
  9.3.1 Menopause
  9.3.2 Hypothyroidism
  9.3.3 Male Hypogonadism
  9.3.4 Growth Hormone Deficiency
 9.4 Historic and Forecasted Market Size By Route Of Administration
  9.4.1 Oral
  9.4.2 Transdermal
  9.4.3 Parenteral
 9.5 Historic and Forecasted Market Size By Distribution Channel
  9.5.1 Hospital Pharmacies
  9.5.2 Retails Pharmacies & Stores
  9.5.3 Online Pharmacies

Chapter 10: North America Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2017-2032
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Therapy Type
  10.4.1 Estrogen and Combinations Replacement Therapy
  10.4.2 Growth Hormone Replacement Therapy
  10.4.3 Thyroid Hormone Replacement Therapy
  10.4.4 Testosterone Hormone Replacement Therapy
 10.5 Historic and Forecasted Market Size By Indication
  10.5.1 Menopause
  10.5.2 Hypothyroidism
  10.5.3 Male Hypogonadism
  10.5.4 Growth Hormone Deficiency
 10.6 Historic and Forecasted Market Size By Route Of Administration
  10.6.1 Oral
  10.6.2 Transdermal
  10.6.3 Parenteral
 10.7 Historic and Forecasted Market Size By Distribution Channel
  10.7.1 Hospital Pharmacies
  10.7.2 Retails Pharmacies & Stores
  10.7.3 Online Pharmacies
 10.8 Historic and Forecast Market Size by Country
  10.8.1 U.S.
  10.8.2 Canada
  10.8.3 Mexico

Chapter 11: Europe Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2017-2032
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Therapy Type
  11.4.1 Estrogen and Combinations Replacement Therapy
  11.4.2 Growth Hormone Replacement Therapy
  11.4.3 Thyroid Hormone Replacement Therapy
  11.4.4 Testosterone Hormone Replacement Therapy
 11.5 Historic and Forecasted Market Size By Indication
  11.5.1 Menopause
  11.5.2 Hypothyroidism
  11.5.3 Male Hypogonadism
  11.5.4 Growth Hormone Deficiency
 11.6 Historic and Forecasted Market Size By Route Of Administration
  11.6.1 Oral
  11.6.2 Transdermal
  11.6.3 Parenteral
 11.7 Historic and Forecasted Market Size By Distribution Channel
  11.7.1 Hospital Pharmacies
  11.7.2 Retails Pharmacies & Stores
  11.7.3 Online Pharmacies
 11.8 Historic and Forecast Market Size by Country
  11.8.1 Germany
  11.8.2 U.K.
  11.8.3 France
  11.8.4 Italy
  11.8.5 Russia
  11.8.6 Spain

Chapter 12: Asia-Pacific Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2017-2032
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Therapy Type
  12.4.1 Estrogen and Combinations Replacement Therapy
  12.4.2 Growth Hormone Replacement Therapy
  12.4.3 Thyroid Hormone Replacement Therapy
  12.4.4 Testosterone Hormone Replacement Therapy
 12.5 Historic and Forecasted Market Size By Indication
  12.5.1 Menopause
  12.5.2 Hypothyroidism
  12.5.3 Male Hypogonadism
  12.5.4 Growth Hormone Deficiency
 12.6 Historic and Forecasted Market Size By Route Of Administration
  12.6.1 Oral
  12.6.2 Transdermal
  12.6.3 Parenteral
 12.7 Historic and Forecasted Market Size By Distribution Channel
  12.7.1 Hospital Pharmacies
  12.7.2 Retails Pharmacies & Stores
  12.7.3 Online Pharmacies
 12.8 Historic and Forecast Market Size by Country
  12.8.1 China
  12.8.2 India
  12.8.3 Japan
  12.8.4 Southeast Asia

Chapter 13: South America Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2017-2032
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Therapy Type
  13.4.1 Estrogen and Combinations Replacement Therapy
  13.4.2 Growth Hormone Replacement Therapy
  13.4.3 Thyroid Hormone Replacement Therapy
  13.4.4 Testosterone Hormone Replacement Therapy
 13.5 Historic and Forecasted Market Size By Indication
  13.5.1 Menopause
  13.5.2 Hypothyroidism
  13.5.3 Male Hypogonadism
  13.5.4 Growth Hormone Deficiency
 13.6 Historic and Forecasted Market Size By Route Of Administration
  13.6.1 Oral
  13.6.2 Transdermal
  13.6.3 Parenteral
 13.7 Historic and Forecasted Market Size By Distribution Channel
  13.7.1 Hospital Pharmacies
  13.7.2 Retails Pharmacies & Stores
  13.7.3 Online Pharmacies
 13.8 Historic and Forecast Market Size by Country
  13.8.1 Brazil
  13.8.2 Argentina

Chapter 14: Middle East & Africa Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2017-2032
 14.1 Key Market Trends, Growth Factors and Opportunities
 14.2 Impact of Covid-19
 14.3 Key Players
 14.4 Key Market Trends, Growth Factors and Opportunities
 14.4 Historic and Forecasted Market Size By Therapy Type
  14.4.1 Estrogen and Combinations Replacement Therapy
  14.4.2 Growth Hormone Replacement Therapy
  14.4.3 Thyroid Hormone Replacement Therapy
  14.4.4 Testosterone Hormone Replacement Therapy
 14.5 Historic and Forecasted Market Size By Indication
  14.5.1 Menopause
  14.5.2 Hypothyroidism
  14.5.3 Male Hypogonadism
  14.5.4 Growth Hormone Deficiency
 14.6 Historic and Forecasted Market Size By Route Of Administration
  14.6.1 Oral
  14.6.2 Transdermal
  14.6.3 Parenteral
 14.7 Historic and Forecasted Market Size By Distribution Channel
  14.7.1 Hospital Pharmacies
  14.7.2 Retails Pharmacies & Stores
  14.7.3 Online Pharmacies
 14.8 Historic and Forecast Market Size by Country
  14.8.1 Saudi Arabia
  14.8.2 South Africa

Chapter 15 Investment Analysis

Chapter 16 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. HORMONE REPLACEMENT THERAPY MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. HORMONE REPLACEMENT THERAPY MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. HORMONE REPLACEMENT THERAPY MARKET COMPETITIVE RIVALRY
TABLE 005. HORMONE REPLACEMENT THERAPY MARKET THREAT OF NEW ENTRANTS
TABLE 006. HORMONE REPLACEMENT THERAPY MARKET THREAT OF SUBSTITUTES
TABLE 007. HORMONE REPLACEMENT THERAPY MARKET BY THERAPY TYPE
TABLE 008. ESTROGEN AND COMBINATIONS REPLACEMENT THERAPY MARKET OVERVIEW (2016-2028)
TABLE 009. GROWTH HORMONE REPLACEMENT THERAPY MARKET OVERVIEW (2016-2028)
TABLE 010. THYROID HORMONE REPLACEMENT THERAPY MARKET OVERVIEW (2016-2028)
TABLE 011. TESTOSTERONE HORMONE REPLACEMENT THERAPY MARKET OVERVIEW (2016-2028)
TABLE 012. HORMONE REPLACEMENT THERAPY MARKET BY INDICATION
TABLE 013. MENOPAUSE MARKET OVERVIEW (2016-2028)
TABLE 014. HYPOTHYROIDISM MARKET OVERVIEW (2016-2028)
TABLE 015. MALE HYPOGONADISM MARKET OVERVIEW (2016-2028)
TABLE 016. GROWTH HORMONE DEFICIENCY MARKET OVERVIEW (2016-2028)
TABLE 017. HORMONE REPLACEMENT THERAPY MARKET BY ROUTE OF ADMINISTRATION
TABLE 018. ORAL MARKET OVERVIEW (2016-2028)
TABLE 019. TRANSDERMAL MARKET OVERVIEW (2016-2028)
TABLE 020. PARENTERAL MARKET OVERVIEW (2016-2028)
TABLE 021. HORMONE REPLACEMENT THERAPY MARKET BY DISTRIBUTION CHANNEL
TABLE 022. HOSPITAL PHARMACIES MARKET OVERVIEW (2016-2028)
TABLE 023. RETAILS PHARMACIES & STORES MARKET OVERVIEW (2016-2028)
TABLE 024. ONLINE PHARMACIES MARKET OVERVIEW (2016-2028)
TABLE 025. NORTH AMERICA HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE (2016-2028)
TABLE 026. NORTH AMERICA HORMONE REPLACEMENT THERAPY MARKET, BY INDICATION (2016-2028)
TABLE 027. NORTH AMERICA HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 028. NORTH AMERICA HORMONE REPLACEMENT THERAPY MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 029. N HORMONE REPLACEMENT THERAPY MARKET, BY COUNTRY (2016-2028)
TABLE 030. EUROPE HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE (2016-2028)
TABLE 031. EUROPE HORMONE REPLACEMENT THERAPY MARKET, BY INDICATION (2016-2028)
TABLE 032. EUROPE HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 033. EUROPE HORMONE REPLACEMENT THERAPY MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 034. HORMONE REPLACEMENT THERAPY MARKET, BY COUNTRY (2016-2028)
TABLE 035. ASIA PACIFIC HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE (2016-2028)
TABLE 036. ASIA PACIFIC HORMONE REPLACEMENT THERAPY MARKET, BY INDICATION (2016-2028)
TABLE 037. ASIA PACIFIC HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 038. ASIA PACIFIC HORMONE REPLACEMENT THERAPY MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 039. HORMONE REPLACEMENT THERAPY MARKET, BY COUNTRY (2016-2028)
TABLE 040. MIDDLE EAST & AFRICA HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE (2016-2028)
TABLE 041. MIDDLE EAST & AFRICA HORMONE REPLACEMENT THERAPY MARKET, BY INDICATION (2016-2028)
TABLE 042. MIDDLE EAST & AFRICA HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 043. MIDDLE EAST & AFRICA HORMONE REPLACEMENT THERAPY MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 044. HORMONE REPLACEMENT THERAPY MARKET, BY COUNTRY (2016-2028)
TABLE 045. SOUTH AMERICA HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE (2016-2028)
TABLE 046. SOUTH AMERICA HORMONE REPLACEMENT THERAPY MARKET, BY INDICATION (2016-2028)
TABLE 047. SOUTH AMERICA HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 048. SOUTH AMERICA HORMONE REPLACEMENT THERAPY MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 049. HORMONE REPLACEMENT THERAPY MARKET, BY COUNTRY (2016-2028)
TABLE 050. ABBOTT LABORATORIES: SNAPSHOT
TABLE 051. ABBOTT LABORATORIES: BUSINESS PERFORMANCE
TABLE 052. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 053. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 053. BAYER AG: SNAPSHOT
TABLE 054. BAYER AG: BUSINESS PERFORMANCE
TABLE 055. BAYER AG: PRODUCT PORTFOLIO
TABLE 056. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 056. ELI LILLY AND COMPANY: SNAPSHOT
TABLE 057. ELI LILLY AND COMPANY: BUSINESS PERFORMANCE
TABLE 058. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 059. ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 059. F. HOFFMANN-LA ROCHE LTD. (GENENTECH: SNAPSHOT
TABLE 060. F. HOFFMANN-LA ROCHE LTD. (GENENTECH: BUSINESS PERFORMANCE
TABLE 061. F. HOFFMANN-LA ROCHE LTD. (GENENTECH: PRODUCT PORTFOLIO
TABLE 062. F. HOFFMANN-LA ROCHE LTD. (GENENTECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 062. INC.): SNAPSHOT
TABLE 063. INC.): BUSINESS PERFORMANCE
TABLE 064. INC.): PRODUCT PORTFOLIO
TABLE 065. INC.): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 065. HISAMITSU PHARMACEUTICAL CO. INC. (NOVEN PHARMACEUTICALS INC.): SNAPSHOT
TABLE 066. HISAMITSU PHARMACEUTICAL CO. INC. (NOVEN PHARMACEUTICALS INC.): BUSINESS PERFORMANCE
TABLE 067. HISAMITSU PHARMACEUTICAL CO. INC. (NOVEN PHARMACEUTICALS INC.): PRODUCT PORTFOLIO
TABLE 068. HISAMITSU PHARMACEUTICAL CO. INC. (NOVEN PHARMACEUTICALS INC.): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 068. MERCK KGAA: SNAPSHOT
TABLE 069. MERCK KGAA: BUSINESS PERFORMANCE
TABLE 070. MERCK KGAA: PRODUCT PORTFOLIO
TABLE 071. MERCK KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 071. MYLAN N.V. (VIATRIS INC.): SNAPSHOT
TABLE 072. MYLAN N.V. (VIATRIS INC.): BUSINESS PERFORMANCE
TABLE 073. MYLAN N.V. (VIATRIS INC.): PRODUCT PORTFOLIO
TABLE 074. MYLAN N.V. (VIATRIS INC.): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 074. NOVARTIS INTERNATIONAL AG: SNAPSHOT
TABLE 075. NOVARTIS INTERNATIONAL AG: BUSINESS PERFORMANCE
TABLE 076. NOVARTIS INTERNATIONAL AG: PRODUCT PORTFOLIO
TABLE 077. NOVARTIS INTERNATIONAL AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 077. NOVO NORDISK A/S: SNAPSHOT
TABLE 078. NOVO NORDISK A/S: BUSINESS PERFORMANCE
TABLE 079. NOVO NORDISK A/S: PRODUCT PORTFOLIO
TABLE 080. NOVO NORDISK A/S: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 080. PFIZER INC.: SNAPSHOT
TABLE 081. PFIZER INC.: BUSINESS PERFORMANCE
TABLE 082. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 083. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. HORMONE REPLACEMENT THERAPY MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. HORMONE REPLACEMENT THERAPY MARKET OVERVIEW BY THERAPY TYPE
FIGURE 012. ESTROGEN AND COMBINATIONS REPLACEMENT THERAPY MARKET OVERVIEW (2016-2028)
FIGURE 013. GROWTH HORMONE REPLACEMENT THERAPY MARKET OVERVIEW (2016-2028)
FIGURE 014. THYROID HORMONE REPLACEMENT THERAPY MARKET OVERVIEW (2016-2028)
FIGURE 015. TESTOSTERONE HORMONE REPLACEMENT THERAPY MARKET OVERVIEW (2016-2028)
FIGURE 016. HORMONE REPLACEMENT THERAPY MARKET OVERVIEW BY INDICATION
FIGURE 017. MENOPAUSE MARKET OVERVIEW (2016-2028)
FIGURE 018. HYPOTHYROIDISM MARKET OVERVIEW (2016-2028)
FIGURE 019. MALE HYPOGONADISM MARKET OVERVIEW (2016-2028)
FIGURE 020. GROWTH HORMONE DEFICIENCY MARKET OVERVIEW (2016-2028)
FIGURE 021. HORMONE REPLACEMENT THERAPY MARKET OVERVIEW BY ROUTE OF ADMINISTRATION
FIGURE 022. ORAL MARKET OVERVIEW (2016-2028)
FIGURE 023. TRANSDERMAL MARKET OVERVIEW (2016-2028)
FIGURE 024. PARENTERAL MARKET OVERVIEW (2016-2028)
FIGURE 025. HORMONE REPLACEMENT THERAPY MARKET OVERVIEW BY DISTRIBUTION CHANNEL
FIGURE 026. HOSPITAL PHARMACIES MARKET OVERVIEW (2016-2028)
FIGURE 027. RETAILS PHARMACIES & STORES MARKET OVERVIEW (2016-2028)
FIGURE 028. ONLINE PHARMACIES MARKET OVERVIEW (2016-2028)
FIGURE 029. NORTH AMERICA HORMONE REPLACEMENT THERAPY MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 030. EUROPE HORMONE REPLACEMENT THERAPY MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 031. ASIA PACIFIC HORMONE REPLACEMENT THERAPY MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 032. MIDDLE EAST & AFRICA HORMONE REPLACEMENT THERAPY MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 033. SOUTH AMERICA HORMONE REPLACEMENT THERAPY MARKET OVERVIEW BY COUNTRY (2016-2028)